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ABSTRACT  
Medicinal plants have been documented as an important source for discovering new pharmaceutical molecules that have been used to treat 
serious diseases. Strikingly, previous reports stated that natural products and their derived compounds exhibit lesser side effects  and improved 
efficacy than other synthetic counterparts. Physostigmine, a parasympathomimetic plant alkaloid isolated from the West African perennial 
shrub Physostigma venenosum, it shows a narrow therapeutic index and a short life span, despite its ability to penetrate the blood-brain barrier 
(BBB). It is a widely known reversible butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE) inhibitor and has been document ed to 
treat various ailments such as Alzheimer’s disease. Pharmacologically, physostigmine was first reported as an antidote for atropine 
scopolamine and belladonna alkaloids toxicity. Recently, it has been documented as a therapy for treating several ailments including glaucoma, 
myasthenia gravis and the intoxication caused by tricyclic antidepressant overdoses, anti-histamines, antipsychotics, and benzodiazepines. 
Physostigmine has been reported to be absorbed from the gastrointestinal tract and showed short half-life, as, after the oral administration of 2 
mg of physostigmine salicylate, the peak plasma concentration reached to 30 minutes. This review examines the biological activities, 
pharmacokinetics, and toxicity of physostigmine extracted from P. venenosum. 
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INTRODUCTION 
Physostigmine, a parasympathomimetic plant alkaloid 
isolated from Physostigma venenosum, the famous West 
African perennial shrub and it shows a narrow therapeutic 
index and a short life span, despite its ability to penetrate 
the blood-brain barrier (BBB) [1]. Moreover, physostigmine 
has been extracted from Streptomyces pseudogriseolus 
cultures. Physostigmine acts by interfering with the 
metabolism of acetylcholine (ACh) (Fig 1). It is a covalent 
(reversible-bond hydrolyzed and released) 
butyrylcholinesterase (BuChE) and acetylcholinesterase 
(AChE) inhibitor in the plasma, erythrocytes, and brain; 
AChE is the enzyme that is responsible for the ACh 
breakdown in the synaptic cleft of the neuromuscular 
junction [2] and it acts by indirect stimulation of nicotinic as 
well as muscarinic ACh receptors. 
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Figure 1: The pharmacological activities of physostigmine 
 
Initially, physostigmine was reported as a remedy for 
atropine poisoning [3]. Nowadays, it has been documented as 
a therapy for the treatment of several ailments including 
glaucoma, myasthenia gravis [4], atropine, scopolamine, and 
belladonna alkaloids intoxication [5], and the intoxication 
caused by tricyclic antidepressants overdoses [6], anti-
histamines [7], antipsychotics [8], and benzodiazepines [4]. 
Physostigmine also possesses an important role as a 
significant protective compound toward organophosphate 
poisoning by binding with the active groups in AChE 
reversibly [9]. 
CHEMICAL STRUCTURE 
Physostigmine (Fig 2; C15H21N3O2) a lipid-soluble tertiary 
ammonium compound that has a pKa value of 7.9 and easily 
ionized in the pH of the brain and blood [10]. The following 
physostigmine structure was first detected in 1925 
(1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-
b]indo-5-ol-methylcarbamate) [4].   
 
Figure 2: Chemical structure of physostigmine 
PHYSOSTIGMINE SYNTHESIS 
Synthetically, physostigmine has been synthesized by 
different methods, one of them performed in the presence of 
aluminum chloride by the reaction of  α-
bromopropionyl bromide with p-ethoxymethylaniline 
resulting in 1,3-dimethyl-5-ethoxyindolin-2-one. Afterward, 
in the presence of sodium ethoxide, chloracetonitrile reacts 
with 1,3-dimethyl-5-ethoxyindolin-2-one and results in 1,3-
dimethyl-5-ethoxy-3-cyanomethylindolin-2-one. 
The nitrile group reduction to amine group has occurred that 
is additionally methoxided and resulted in 1, 3-dimethyl-5-
ethoxy-3-(β methylaminoethyl) indolin-2-one. After that, 
the carbonyl group reduction is occurred to form amino 
alcohol by which its dehydration results in 1,3a,8-trimethyl-
2,3,3a,8a-tetrahydropyrrolo[2,3b]-5-ethoxyindol formation. 
The hydrogen bromide was used to remove the ethoxy-
protecting group resulting in a compound containing 
a phenol hydroxyl group that is further reacted with methyl 
isocyanate to give physostigmine [11].  
PHARMACOKINETICS  
Physostigmine has been documented to be absorbed from 
the gastrointestinal tract and other mucous membranes with 
an oral bioavailability between (1-8%) [12]. Physostigmine 
has been documented to show short half-life, as after the oral 
administration of 2 mg of physostigmine salicylate, the peak 
plasma concentration reached to 30 minutes, whereas after 
oral administration of 4 mg, the peak serum levels reached to 
45 minutes and become undetectable within 3 hours [12, 13]. 
Once physostigmine enters the blood circulation, it 
penetrates the BBB smoothly and subsequently inactivated 
by the plasma cholinesterase. Additionally, physostigmine is 
metabolized rapidly from the body due to the presence of 
plasma esterase that leads to its hydrolytic cleavage at the 
ester bond and, consequently, results in the loss of its 
pharmacological activity [14, 15]. Physostigmine has been 
documented to be used as an antidote for anticholinergic 
toxicity of antihistamines, atropine, tricyclic antidepressants, 
and phenothiazine because of its ability to spread to the 
central nervous system (CNS) [16]. 
MECHANISM OF ACTION OF PHYSOSTIGMINE  
Physostigmine, a cholinergic drug that acts by inhibiting the 
AChE and BuChE enzymes that break down acetylcholine, 
thus increasing ACh amounts at cholinergic synapsis in the 
central and peripheral nervous systems and, consequently, 
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accumulate at the muscarinic or nicotinic receptors at the 
synapse sites and promoting the muscarinic, nicotinic and 
CNS activities [17]. Regarding the muscarinic receptor effects, 
physostigmine causes increased urination and aqueous 
humor production, decreased pupil size, increased salivation, 
increased the secretions of the gastrointestinal tract, and 
sweating [18]. Nicotinic effects are those influencing 
sympathetic ganglia or striated muscle such as fasciculation, 
cramps, high blood pressure, twitching, tachycardia, and 
weakness [19], while convulsions, ataxia, and coma are those 
of the CNS effects symptoms [18]. 
ALZHEIMER’S DISEASE AND PHYSOSTIGMINE  
Nowadays, AChE is considered the most important molecular 
target for treating dementia in AD, therefore, 
acetylcholinesterase inhibitors (AChEIs) are currently 
considered to be one of two drug categories approved to 
treat AD [20,  21]. All drugs act by promoting the cholinergic 
deficit, thereby, they reveal the potential efficacy of the 
behavioral, functional, and cognitive symptoms of AD [22]. A 
significant loss in the cholinergic neurons has been observed 
in the postmortem brains infected with AD, which are widely 
disseminated in the hippocampus, amygdala, and neocortex 
[23]. Decreased the cortical choline acetyltransferase efficacy 
is related to the number of aging plaques and cognitive 
decline in AD patients [24]. Physostigmine was the first 
nonselective reversible AChE and BuChE inhibitor 
investigated for treating AD [1], thus increasing central 
cholinergic neurotransmission. In the in vivo experiments, 
physostigmine enhances memory in elderly primates [25], as 
well as primates with amnesia caused by scopolamine, 
whereas in clinical trials physostigmine has shown improved 
cognitive function in patients with AD [26]. 
Combination Therapy of Physostigmine with Drugs 
against Alzheimer’s disease 
Nowadays, combination chemotherapies are being reported 
to alleviate serious diseases, including pulmonary 
tuberculosis, malignancy, immune deficiency syndrome, AD, 
and some protozoal diseases to promote higher therapeutic 
efficacy [27-30]. Schmitt et al. [31] documented the combined 
effect of selegiline with AChE inhibitors such as 
physostigmine or tacrine in AD patients, as well as AChE 
inhibitor and α-lipoic acid AChE inhibitors are very likely to 
be part of any AD combination regimen [32]. 
DOSE 
Recently, Orhan et al. [1] investigated that physostigmine has 
an LD50 of 3 mg/kg in mice. Moreover, Van Dyck et al. [33] 
documented that slow-release physostigmine salicylate at 18, 
24, and 30 mg/day could be a potential and safe drug for 
treating AD for 6 weeks. The recommended adult dose is 
ranged from 0.5 to 2 mg [34], while Kaye. [35] revealed the 
minimal lethal dose of physostigmine to be 60 mg/70 
kg/person and its chemotherapeutic blood level is ranged 
from 0.001 to 0.01 mg/L [36].  
TOXIC SIDE EFFECTS 
Physostigmine, an AChE inhibitor, which stimulates ACh 
hydrolysis to choline and acetic acid. Therefore, 
physostigmine can produce acute toxic effects and it can 
cause muscarinic receptor stimulation including nausea, 
vomiting, diarrhea, abdominal pain, respiratory tract 
secretions, hypersalivation, seizures, Diaphoresis, 
Tachycardia, blurred vision, bradycardia and atrial 
fibrillation [37]. Additionally, it led to the stimulation of 
nicotinic receptors, inducing paralysis, weakness, muscle 
twitching and stimulation of cholinergic receptors in the CNS 
followed by CNS depression, convulsions, coma, and finally 
death. The short plasma half-life and the first-pass 
metabolism of physostigmine inhibited its clinical use in 
treating AD. Therefore, to overcome this problem, novel 
slow-release physostigmine salicylate (Synapton) 
preparation was developed to produce sustainable blood 
levels [33, 38].  
To be noted, death resulted from physostigmine overdose is 
commonly attributed to pulmonary edema and/or failure of 
respiration and the duration of death is ranged between 5 
min-24 h based on the physostigmine dose and route of 
administration [15]. Recently, synthetic physostigmine 
derivatives such as phenserine and eptastigmine have been 
developed and they revealed strong inhibition of AChE and 
demonstrated improved cognitive functions in preclinical 
and clinical studies by indirect stimulation of nicotinic as 
well as muscarinic ACh receptors [21]. Moreover, heptyl 
physostigmine, the physostigmine salt form, which showed 
higher lipophilicity, less toxicity than physostigmine while 
maintaining AChE inhibitor property and it can pass easily 
through BBB. Its use has been reported in the treatment of 
the CNS symptoms caused by scopolamine, atropine and 
other anticholinergic overdoses [34]. 
CONTRAINDICATIONS 
Physostigmine was contraindicated in patients with 
hyperthyroidism, angle-closure glaucoma, hypotension, 
asthma, diabetes, vagal tone increase, gastrointestinal or 
urogenital tract obstruction, gastroesophageal reflux 
disorder, bradycardia, gangrene, peptic ulcer, cardiovascular 
and seizure disorders. Moreover, it is contraindicated to be 
administered with choline esters and depolarizing 
neuromuscular blockers or a salicylate/sulfite allergy [18]. 
Furthermore, it is contraindicated for patients with QRS 
prolongation on electrocardiogram or those with a history of 
QRS medication overdose [37]. 
CONCLUSION 
Physostigmine, a lipid-soluble tertiary amine carbamate 
plant alkaloid that was first reported as an antidote to 
atropine toxicity. It is a famous reversible BuChE and AChE 
inhibitor and it has been used in treating different diseases 
including AD. The finding that physostigmine can combine 
with other drugs is a property that can be explored in the 
chemotherapies development against AD. However, its 
clinical use as a therapy has been prohibited due to the 
existence of the toxic side effects and its short half-life, 
therefore, new synthetic derivatives such as phenserine, 
eptastigmine, heptyl physostigmine and extended-release 
formulation of physostigmine salicylate (Synapton) have 
been developed to produce sustainable blood levels and 
overcome the above-mentioned problems. 
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